Stay updated with breaking news from Chul Cho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.
Man Chul Cho M.D. psychiatry office is located in the heart of Koreatown, Los Angeles. With over 40 years of experience in the field of psychiatry, Dr…
In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Early antitumor activity has been observed in patients with metastatic non–small cell lung cancer treated with the combination of sacituzumab govitecan-hziy and pembrolizumab in the first-line setting.
Treatment with repotrectinib in patients with ROS1-positive non–small cell lung cancer, specifically those who were tyrosine kinase inhibitor-naïve or -pretreated, continued to demonstrate durable clinical activity, as well as durable intracranial responses.